Injectable cross-linked rhCollagen scaffold combined with PRP for soft tissue repair

Racheli Gueta, PhD(1), Frida Grynspan, PhD(2), Tal Amzel, MSc(1), Jasmine Seror, PhD(1), Ofer Levy, MD, MFCH(Orth) FRCS(2), Nadav Orr, PhD(3), Oded Shoseyov, PhD(2,4)

1CollPlant Ltd., Ness-Ziona, Israel;
2Stem Cell Medicine Ltd., Jerusalem, Israel;
3Reading Shoulder Unit, the Royal Berkshire Hospital & the Berkshire Independent Hospital, Reading, UK. The Centre for Sports Medicine and Human Performance, School of Sport and Education Brunel University, London, UK;
4The Robert H. Smith Faculty of Agricultural, Food and Environmental Quality Sciences, The Hebrew University of Jerusalem, Rehovot, Israel.

Introduction

CollPlant has generated a bio-engineered plant line capable of expressing human recombinant type I collagen.

Vergenix™STR is an injectable gel composed of cross-linked human recombinant type I collagen used in combination with autologous platelet rich plasma (PRP).

Upon injection, the complex forms a collagen-fibrin matrix at the injury site and promotes cell migration and tissue repair.

Vergenix™ STR combined with PRP (STR/PRP) is now in clinical trial for the treatment of tendinopathy.

In vitro study: cell proliferation

Normal human dermal fibroblasts (hDF) were seeded on STR/PRP matrix and on thrombin activated PRP under starvation conditions.

- Cell viability is significantly higher on STR/PRP matrix than on PRP clot or starvation medium (control)
- STR/PRP promotes cell proliferation

In vivo study: matrix degradation and growth factors (GFs) release in a subcutaneous rat model

Vergenix™ STR combined with PRP and activated PRP alone were injected subcutaneously in rats. Matrix degradation (weight) and GFs release (GFs content measured by EUSA) were assessed at several time points (0, 7, 14, 21, 30, 45 days)

Degradation

- STR/PRP gradually degrades over time
- STR/PRP weight at d=45 is <0.2% of its original weight
- PRP alone disappears already at day 1

GFs release: GFs content over time

- PRP clot: GFs are released in the first 24 hours
- STR/PRP matrix: the GFs content profile shows a first burst between day 0 and 1 followed by an increase up to day 21 and a consequent decrease up to day 45
- STR/PRP promotes temporary migration of cells which express high level of platelet-derived growth factors (PDGFs) and vascular endothelial growth factors (VEGFs)

In vivo study: Achilles tendon tendinopathy model in rats

Tendinopathy was induced by collagenase injection into the right Common Calcaneal rat's tendon. Treatment was administered a week later, by injection into the same tendon.

Clinical pathology evaluation and histopathological evaluation were performed after 3, 7 and 14 days.

Vergenix™STR combined with PRP promotes:

- Decrease in the incidence of inflammatory mononuclear cells
- Reduction in the severity of immature granulation tissue (i.e. fibroplasia)
- Increase in mature fibrosis.

Summary and Conclusions

- Vergenix™STR is composed of human recombinant type I collagen expressed in transgenic tobacco plants
- Upon injection, Vergenix™STR combined with PRP forms in situ a matrix composed of collagen and fibrin
- STR/PRP matrix reduces inflammation and promotes cell proliferation and tissue healing
- STR/PRP matrix promotes in situ GFs generation and release while gradually degrading
- Both in vivo and in vitro studies showed superior performance of STR/PRP compared to PRP alone